jnj-61178104
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2014 (NCT02243787)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- TNF-alphaBINDING AGENT
TNFA
- Interleukin 17ABINDING AGENT
IL17A
- TNF-alphaINHIBITOR
TNF inhibitor
- Interleukin 17AINHIBITOR
IL17A inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- cova322
- jnj-61178104
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02758392 | Phase 1 | Apr 1, 2016 | Johnson and Johnson |
| NCT02243787 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2014 | Covagen, Sciderm GmbH |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Covagen | For profit | 1 | 1 | 1 | 2014 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2016 |
| Sciderm GmbH | For profit | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1